Search Results - "Tunn, U."

Sentinel node biopsy in soft tissue sarcoma subtypes with a high propensity for regional lymphatic spread—results of a large prospective trial by Andreou, D., Boldt, H., Werner, M., Hamann, C., Pink, D., Tunn, P.-U.

“…The role of sentinel lymph node biopsy (SLNB) in soft tissue sarcoma patients has yet to be determined. We sought to evaluate the role of SLNB in the treatment…”
Get full text

The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols by Andreou, D., Bielack, S.S., Carrle, D., Kevric, M., Kotz, R., Winkelmann, W., Jundt, G., Werner, M., Fehlberg, S., Kager, L., Kühne, T., Lang, S., Dominkus, M., Exner, G.U., Hardes, J., Hillmann, A., Ewerbeck, V., Heise, U., Reichardt, P., Tunn, P. -U.

“…Local recurrence (LR) in osteosarcoma is associated with very poor prognosis. We sought to evaluate which factors correlate with LR in patients who achieved…”
Get full text

Argyria following the use of silver-coated megaprostheses: no association between the development of local argyria and elevated silver levels by Glehr, M, Leithner, A, Friesenbichler, J, Goessler, W, Avian, A, Andreou, D, Maurer-Ertl, W, Windhager, R, Tunn, P-U

“…The aims of this study were to evaluate the incidence of local argyria in patients with silver-coated megaprostheses and to identify a possible association…”
Get more information

Limb-salvage reconstruction with MUTARS® hemipelvic endoprosthesis: A prospective multicenter study by Witte, D, Bernd, L, Bruns, J, Gosheger, G, Hardes, J, Hartwig, E, Lehner, B, Melcher, I, Mutschler, W, Schulte, M, Tunn, P.-U, Wozniak, W, Zahlten-Hinguranage, A, Zeifang, F

“…Abstract Background Limb-sparing surgery with hemipelvic megaprosthetic replacement is often limited by the high rate of associated complications. The aim of…”
Get full text

Outcome following unplanned excision in soft tissue sarcoma: Results of a multicentre study including 728 patients by Smolle, M.A., Tunn, P.-U., Goldenitsch, E., Posch, F., Szkandera, J., Bergovec, M., Liegl-Atzwanger, B., Leithner, A.

Get full text

Differentiation of myxoid liposarcoma by magnetic resonance imaging: a histopathologic correlation by Löwenthal, D, Zeile, M, Niederhagen, M, Fehlberg, S, Schnapauff, D, Pink, D, Tunn, P U, Reichardt, P, Hamm, B, Dudeck, O

“…Myxoid liposarcomas represent a heterogeneous group of soft tissue tumors in which prognosis is dependent on differentiation. To identify magnetic resonance…”
Get more information

Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy by Tunn, U W, Canepa, G, Kochanowsky, A, Kienle, E

“…Background: Intermittent androgen deprivation (IAD) for prostate cancer was studied with the objective of reducing the side effects of treatment and…”
Get full text

Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe by Tunn, U W, Wiedey, K

“…This multicentre European study compared the safety and tolerability of the existing 11.25 mg 3-month depot of leuprorelin acetate with a new 30 mg 6-month…”
Get full text

Sentinel node biopsy in synovial sarcoma by Tunn, P.-U, Andreou, D, Illing, H, Fleige, B, Dresel, S, Schlag, P.M

“…Abstract Aims To examine the relevance of sentinel node biopsy in patients with synovial sarcoma. Methods Between July 2004 and February 2007 11 consecutive…”
Get full text

Management of prostate-specific antigen relapse in prostate cancer: a European Consensus by Boccon-Gibod, L, Djavan, W B, Hammerer, P, Hoeltl, W, Kattan, M W, Prayer-Galetti, T, Teillac, P, Tunn, U W

“…A European Consensus on the management of prostate-specific antigen (PSA) relapse in patients with prostate cancer has been formulated. The key recommendations…”
Get more information

Computed tomographic criteria for the discrimination of subcentimeter lung nodules in patients with soft-tissue sarcomas by Dudeck, Oliver, Zeile, M, Andreou, D, Schnapauff, D, Pech, M, Wieners, G, Ricke, J, Reichardt, P, Tunn, P.-U

“…Abstract The aim of this study was to identify criteria for nodule characterization on chest computed tomography in patients with soft tissue sarcomas. In 195…”
Get full text

Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group by Stacchiotti, S., Gronchi, A., Fossati, P., Akiyama, T., Alapetite, C., Baumann, M., Blay, J.Y., Bolle, S., Boriani, S., Bruzzi, P., Capanna, R., Caraceni, A., Casadei, R., Colia, V., Debus, J., Delaney, T., Desai, A., Dileo, P., Dijkstra, S., Doglietto, F., Flanagan, A., Froelich, S., Gardner, P.A., Gelderblom, H., Gokaslan, Z.L., Haas, R., Heery, C., Hindi, N., Hohenberger, P., Hornicek, F., Imai, R., Jeys, L., Jones, R.L., Kasper, B., Kawai, A., Krengli, M., Leithner, A., Logowska, I., Martin Broto, J., Mazzatenta, D., Morosi, C., Nicolai, P., Norum, O.J., Patel, S., Penel, N., Picci, P., Pilotti, S., Radaelli, S., Ricchini, F., Rutkowski, P., Scheipl, S., Sen, C., Tamborini, E., Thornton, K.A., Timmermann, B., Torri, V., Tunn, P.U., Uhl, M., Yamada, Y., Weber, D.C., Vanel, D., Varga, P.P., Vleggeert-Lankamp, C.L.A., Casali, P.G., Sommer, J.

“…Chordomas are rare, malignant bone tumors of the skull-base and axial skeleton. Until recently, there was no consensus among experts regarding appropriate…”
Get full text

Management of locally advanced prostate cancer: a European consensus by Boccon-Gibod, L, Bertaccini, A, Bono, A V, Dev Sarmah, B, Höltl, W, Mottet, N, Tunn, U, Zamboglou, N

“…This report summarises the findings of a European Consensus Group review of current standards of care in locally advanced prostate cancer defined as (a)…”
Get more information

Intermittent androgen blockade in prostate cancer: rationale and clinical experience by Wolff, J M, Tunn, U W

“…Cancer of the prostate continues to be one of the most common malignancies in men in Europe, with a large number of patients presenting with advanced disease…”
Get more information

Resection of soft tissue sarcoma of the lower limb after evaluation of vascular invasion with intraoperative intravascular ultrasonography by Hünerbein, M., Hohenberger, P., Stroszczynski, C., Bartelt, N., Schlag, P. M., Tunn, P. U.

“…Background: This study investigated the value of intravascular ultrasonography (IVUS) in the intraoperative assessment of vascular invasion of soft tissue…”
Get full text

Intermittent endocrine therapy of prostate cancer by Tunn, U W

“…Permanent androgen suppression is the therapy of choice in the treatment of advanced prostate cancer. Intermittent androgen deprivation (IAD) through…”
Get more information

The significance of serum levels of insulin‐like growth factor‐1 in patients with prostate cancer by Kurek, R., Tunn, U.W., Eckart, O., Aumüller, G., Wong, J., Renneberg, H.

“…Objectives To compare the serum levels of insulin‐like growth factor‐1 (IGF‐1) in patients with prostate cancer and in control patients with no malignancy, and…”
Get full text

Chirurgische Therapie von Weichteilsarkomen der Extremitäten by Dürr, H.R., Bakhshai, Y., Tunn, P.-U.

“…Zusammenfassung Hintergrund Unter kurativer Intention ist die operative Therapie im multimodalen Behandlungskonzept der Patienten mit einem Weichteilsarkom der…”
Get full text

Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer by Kurek, R, Renneberg, H, Lübben, G, Kienle, E, Tunn, U W

“…To determine the efficacy, safety and feasibility of intermittent androgen deprivation (IAD) in patients with prostate-specific antigen (PSA) relapse after…”
Get more information

Prognostic relevance of the mitotic count and the amount of viable tumour after neoadjuvant chemotherapy for primary, localised, high-grade soft tissue sarcoma by Andreou, D, Werner, M, Pink, D, Traub, F, Schuler, M, Gosheger, G, Jobke, B, Reichardt, P, Tunn, P U

“…Background: We sought to examine whether mitotic count (MC) and the amount of viable tumour (VT) following neoadjuvant systemic chemotherapy (SC) for primary,…”
Get full text